User:Syed Hassan Abbas Kazmi

Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Syed Hassan Kazmi, MD

Contact:

Email: skazmi@bidmc.harvard.edu


Syed Hassan Kazmi, MD (also published as Syed Hassan Abbas Kazmi, Syed H. A. Kazmi, and Hassan A. Kazmi) is a physician and clinical researcher with peer-reviewed publications in cardiovascular medicine, thrombosis, interventional cardiology, outcomes research, preventive cardiology, PCI, Electrophysiology, AI, and evidence synthesis.

Official profiles (canonical links)

Research focus

  • Cardiovascular outcomes and evidence synthesis (meta-analysis, trial design, protocol development, medical education, agentic AI, imaging assistant, explainable AI or XAI)
  • Antithrombotic therapy and venous thromboembolism (VTE)
  • Post–myocardial infarction risk biology and HDL/ApoA-I therapeutics
  • Cardiovascular devices and ischemia detection systems

Selected peer-reviewed manuscripts

  1. The AngelMed Guardian® System in the Detection of Coronary Artery Occlusion: Current Perspectives. Med Devices (Auckl). 2020;13:1–12. doi:10.2147/MDER.S219865. PMID:32021496. PMCID:PMC6954830.
  2. CSL112 (Apolipoprotein A-I [Human)Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial.] J Cardiovasc Pharmacol Ther. 2022 Jan-Dec;27:10742484221121507. doi: 10.1177/10742484221121507. PMID: 36282079.
  3. Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis. Front Cardiovasc Med. 2021 Dec 13;8:774418. doi: 10.3389/fcvm.2021.774418. PMID: 34966797; PMCID: PMC8710716.
  4. Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials. J Med Virol. 2021. PMID:34370328. PMCID:PMC8427058.
  5. ApoA-I infusion therapies following acute coronary syndrome: Past, present, and future. Curr Atheroscler Rep. 2022;24:585–597. doi:10.1007/s11883-022-01025-7. PMID:35524914. PMCID:PMC9236992.
  6. Early and late recurrent cardiovascular events among high-risk patients with an acute coronary syndrome: Meta-analysis of phase III studies and implications on trial design. Clin Cardiol. 2022;45(3):299–307. doi:10.1002/clc.23773. PMID:35019162. PMCID:PMC8922536.
  7. Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human) for prevention of major adverse cardiovascular events in patients with myocardial infarction.] Eur Heart J Cardiovasc Pharmacother. 2023;9(4):387–398. PMID:36787889. PMCID:PMC10236524.
  8. Cholesterol Efflux Capacity and Measurement Assays: A Novel Biomarker of High-Density Lipoprotein (HDL) Function.
  9. Association of anemia with venous thromboembolism in acutely ill hospitalized patients: an APEX trial substudy. Am J Med. 2018;131(8):972.e1–972.e7. PMID:29660351.
  10. Reduction of cardiovascular mortality and ischemic events in acute medically ill patients: an APEX substudy. Circulation. 2019;139(9):1234–1236. PMID:30802169.
  11. Most promising therapies in interventional cardiology. Curr Cardiol Rep. 2019. PMID:30868280.
  12. The Landscape of Pharmacological Interventional Trials for the Treatment or Prevention of Coronary Artery Disease: Analysis of clinicaltrials.gov Listings From 2008 to 2022. Circulation. 2023;148(Suppl_1):A14710-A.
  13. Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism. Expert Rev Cardiovasc Ther. 2018 Nov;16(11):845-855. doi: 10.1080/14779072.2018.1534068. Epub 2018 Oct 15. PMID: 30296387.


Conference abstracts / presentations


Education & training

Name variants

  • Syed Hassan Kazmi
  • Syed Hassan Abbas Kazmi
  • Syed H A Kazmi
  • Hassan A Kazmi
  • Hassan Kazmi
  • SH Kazmi
  • SHA Kazmi


Authored Pages


Reviewed Pages


Languages

English: Fluent in reading, writing and speaking

Urdu: Fluent in reading, writing and speaking

Hindi: Fluent in speaking

Punjabi: Fluent in reading, writing and speaking

Arabic: Fluent in reading and writing

Persian: Fluent in reading and writing